A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE007 (JPN) · Dr. Dubois
consented 2022-08-05
Adverse events
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-25 (study day 65); relationship: not assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-10-25 (study day 65); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-02-10 (study day 173); relationship: not assessed
Grade 4 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-02-26 (study day 189); relationship: Y; serious criteria: life-threatening
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-03-31 (study day 222); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-05-11 (study day 263); relationship: not assessed
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-11-03 (study day 439); relationship: not assessed
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-11-25 (study day 461); relationship: not assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-12-24 (study day 490); relationship: N
Data queries
No data queries.